Babies treated for acute lymphoblastic leukemia (ALL) whose leukemic cells have a specific chromosomal abnormality do not benefit from bone marrow transplantation, a new study indicates.
In fact, these babies have worse outcomes and increased long-term complications from the procedure. The research indicates that physicians treating these patients should rely on improved chemotherapy.
These results were published in the June issue of the journal Lancet by an international team led by Ching-Hon Pui, M.D., and William Evans, Pharm.D., at St. Jude Children’s Research Hospital. The study casts new light on treatment for childhood ALL patients with chromosomal 11q23 abnormalities in their leukemic cells.
This type of leukemia is most common in babies less than one year old. Study data was derived from childhood ALL patients treated in Western Europe and North America over a 10-year period. About 2 percent of ALL patients, or about 60 patients annually, are diagnosed with this type of leukemia in the U.S.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!